When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
Previous attempts to treat Christine’s Chronic Lymphocytic Leukemia (CLL) had failed. She participated in a clinical trial and subsequently went through a CAR T-cell transplant at the NCI-designated…
In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
